To determine use of psychotropic drugs and weak opioids in hip fracture patients by analysing plasma samples at admission, and compare detected drug frequencies with prescription registry data and drug records.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Use of psychotropic drugs and weak opioids has in previous prescription studies been associated with increased risk of falling and hip fracture.
• Due to substantial nonadherence rates of many drugs, in particular antidepressant agents, risk estimates based on prescription data are subject to considerable uncertainty.
WHAT THIS STUDY ADDS
• The present study detected significantly higher frequencies of antidepressants and benzodiazepines in plasma samples of hip fracture patients than respective prescription frequencies of the same drugs in a matched reference population.
• By being the first to measure drug intake based on plasma analyses, the present study supports that use of antidepressants is associated with increased risk of hip fracture.
• The consistency between detected and recorded drug use in this patient population is poor for many psychotropic agents and weak opioids at hospital admission. 
Introduction
Hip fractures are highly prevalent in older persons, with great implications for morbidity and mortality. Norway is the country with the highest incidence of hip fractures in the world [2, 3] . One risk factor for falls and hip fractures is the use of drugs with side effects that impair balance, such as psychotropic agents [4] [5] [6] [7] and opioid analgesics [8, 9] . In Norway, people aged >65 years represent about 15% of the population [10] , but constitute 35% of the overall consumption of central nervous agents (ATC group N) [11] . Previous studies have shown an increased risk of falls and hip fractures among older people who had been prescribed anxiolytics, hypnotics, antidepressants or weak opioid analgesics [7] [8] [9] [12] [13] [14] . The risk of falls and hip fractures has been estimated to be 1.7-fold increased in older persons using antidepressants compared with older persons not using antidepressants [12] . For hypnotics and anxiolytics, respectively, 1.2-fold and 1.4-fold higher risks of falls and hip fractures in users vs. nonusers have been reported [13] . Regarding use of opioids, the reported relative risk of hip fracture is more inconsistent, and seems to depend on type of drug and treatment duration [8, 9, 15, 16] . Among weak opioids, some studies suggest that use of tramadol is associated with a higher frequency of hip fracture events than use of other agents within this drug class [9, 15] . In addition to the mentioned centrally acting drugs, alcohol consumption is a known risk factor for falls, which is included in the FRAX calculation tool for risk of osteoporotic fractures [17] . In a Finnish study, alcohol was detected in blood samples at admission in 19% of men and 16% of women with hip fracture [18] .
All the studies referred above investigating risk of druginduced falls are based on data from prescription registries based on dispensing from pharmacies. This implies uncertainty as to whether drugs actually have been consumed or not. This issue is particularly relevant for antidepressants, where nonadherence to drug treatment is as high as 50% [19] . These substantial nonadherence frequencies imply that studies based on prescription data are subject to considerable uncertainty regarding risk estimates.
So far, no studies have investigated the risk of falling and hip fracture associated to drug use as measured by objective analyses in blood samples. Thus, the aim of this study was to determine use of psychotropic agents and weak opioid analgesics in older hip fracture patients by analysing plasma samples collected at admission and compare detected drug frequencies with prescription registry data. Moreover, we compared the consistency between recorded and detected drugs.
Methods

Patient inclusion
In this observational study, hip fracture patients aged ≥65 years were prospectively included on admission to an orthogeriatric unit at Diakonhjemmet Hospital, Oslo, Norway. The inclusion was carried out between ultimo 2011 and primo 2013 until 250 hip fracture patients were enrolled in the study. Patients who: (i) were terminally ill; (ii) had a dementia diagnosis; (iii) lived in nursing homes; or (iv) were unable to give written informed consent, were excluded from the study. Routine blood samples were taken from all patients at admission, before initiation of any medical treatment due to the fracture event. These samples were later applied for detection of psychotropic drugs and weak opioids in the patients' blood/plasma withdrawn at hospitalization. According to standard procedure, none of the assayed drugs were administered to relieve pain or anxiety between the falling event and hospital admission. All agents that were searched for in the plasma samples, including codeine, are only available on prescription in Norway.
The study was approved by the Regional Committee for Medical and Health Research Ethics (ref. 2011/750) and the Hospital Investigational Review Board. Written, informed consent for inclusion in the study was, dependent on the clinical situation, obtained pre-or postoperatively. In addition to accepting that additional pharmacological analyses were performed using routine blood samples, the patients consented that information from the medical records was withdrawn for research purpose. The patients were not asked about recent alcohol intake when consent for inclusion in the study was obtained.
Drug analyses
Analyses of drugs in plasma samples were performed by validated and certified ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) methods developed for routine therapeutic drug monitoring analyses at the Center for Psychopharmacology, Diakonhjemmet Hospital, Norway. The methods were designed for simultaneous determination of multiple agents within the same therapeutic classes, and included analyses of the following: (i) antidepressants -amitriptyline, bupropion, citalopram/escitalopram, clomipramine, duloxetine, fluoxetine, fluvoxamine, mianserin, mirtazapine, nortriptyline, paroxetine, sertraline, trimipramine and venlafaxine; (ii) antipsychotics -amisulpride, aripiprazole, chlorprothixene, clozapine, flupentixol, haloperidol, levomepromazine, olanzapine, paliperidone, perphenazine, quetiapine, risperidone, sertindole, ziprasidone and zuclopentixol; (iii) antiepileptics/mood stabilizers -carbamazepine, eslicarbazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate and valproate; (iv) benzodiazepines -alprazolam, clonazepam, diazepam, flunitrazepam, nitrazepam and oxazepam; (v) z-hypnotics -zolpidem and zopiclone; and (vi) opioids -buprenorphine, codeine and tramadol. The plasma samples were analysed for the potential presence of all these substances, including relevant metabolites for some of the compounds. Presence of oxazepam in plasma samples with combined detection of diazepam was interpreted as diazepam use, and not oxazepam, as the latter is a metabolite of the former.
The sample preparation step was the same for all assays. After precipitation of proteins in a 500 μl plasma sample with 1000 μl acetonitrile-methanol (90/10 vol/vol), centrifuged for 10 minutes at 1800 g at -2°C, 5 μl of the purified plasma samples were injected into an Acquity UPLC system (Waters, Milford, MA, USA) with a Micromass Quattro micro or Quattro premier MS/MS detector (Waters) operated in electrospray ionization-positive mode. Chromatographic separation of all compounds was performed on an Acquity UPLC BEH Shield RP18 column (1.7 μm, 1.0 × 100 mm; Waters). The mobile phase gradients differed between the various assays, but all were based on mixtures of acetonitrile and ammonium acetate buffer (pH 4.8). The total run time was 5.0 min for all assays.
MS/MS detection was performed by multiple reactions monitoring at specific transitions for the different analytes and internal standards. Calibration curves (n = 5) fitted to linear or quadratic polynomial functions gave r 2 > 0.995 for the different analytes. At both extremes of the calibration curves, the intra-and interday validation parameters of imprecision and inaccuracy showed less than 15% deviation (n = 5) for all compounds. For information about detection limits of assayed drugs, see Supplementary Table 1 . For ethanol, the lower limit for reporting/defining use was set to 0.1‰.
Information from medical records
Information on the patients' prescribed drugs prior to admission was retrieved from the medication lists (charts) prepared during hospitalization. Details for preparing drug lists were obtained from the patients themselves or relatives, general practitioners, previous medical records and/or the home nursing. Additional clinical information, such as comorbidity (assessed by Charlson Comorbidity Index [20] ), current chronic diseases, sodium (Na + ) levels, possible ethanol detection upon hospital arrival and details about fall events, was obtained from the medical records.
Data analyses
The frequencies of antidepressants, benzodiazepines, z-hypnotics, codeine and tramadol detected in blood samples of the hip fracture patients were compared with prescription frequencies of the same drugs in an age-, time-and regionmatched population from the Norwegian Prescription Database (NorPD; reference population), which contains information about all prescription drugs dispensed from pharmacies to Norwegian inhabitants, except from drugs administered at institutions such as nursing homes [11] . To estimate frequencies of drug prescriptions in the reference population, demographic data from Statistics Norway were applied [21] . Odds ratios (OR) for drugs detected in plasma samples of hip fracture patients vs. prescription frequencies of the same agents in the reference population were calculated by twotailed Chi-square tests (95% confidence intervals [CI] and P values estimated). Statistical comparisons of detection frequencies in hip fracture patients and prescription frequencies in the reference population were not performed with <10 observations in the former subgroup (due to limited validity of OR estimates). The consistency between drug use as determined by detection in plasma samples and information in medical records of antidepressants, benzodiazepines, z-hypnotics, codeine and tramadol was assessed by simple comparisons.
GraphPad Prism version 6 (GraphPad software Inc. CA) was used for graphical presentation and statistical analyses. P < 0.05 was considered as statistical significance.
Results
During the study period, a total of 582 hip fracture patients aged ≥65 years were admitted to the hospital and considered for inclusion. Reasons why patients were excluded (or not consented) were not systematically recorded, but the majority of the nonincluded patients arrived from nursing homes (predefined exclusion criterion).
Of the 250 included hip fracture patients, all were residents of Oslo, except from one Danish citizen who was on vacation. Median age was 84 years (range 65-102), and 76% of the patients were females (Table 1 ). About half of the patients (54.8%) had Charlson comorbidity index scores of 1 or higher, while 11 patients (4.4%) had scores ≥3 ( Table 1) . As the most common type of somatic illness, cerebrovascular disease was present in 15.2% of the population (Table 1) . Almost all included patients had one or more diseases/conditions that required drug treatment. In total, 221 patients (88.4%) had prescription drugs (regardless of type) recorded in their medication charts at hospitalization.
The assayed psychotropic/analgesic drugs were detected in plasma samples of 158 patients (63%) at hospital admission. The total number of detected drugs ranged between one and five per patient (median 1, mean 1.7). As a merged drug group, z-hypnotics/benzodiazepines (GABAergic agents) were most commonly detected and present in plasma samples of 111 patients (44.4%, Table 2 ). Simultaneous detection of more than one GABAergic agent, for example diazepam combined with zopiclone, was observed in 20 patients (8.0%). Weak opioid analgesics (codeine/tramadol) were the second most commonly detected group of drugs, followed by antidepressants (Table 2) . These agents were present in samples of 63 (25.2%) and 41 (16.4%) of the hip fracture patients, respectively. Alcohol (ethanol) was detected in plasma samples of 19 patients (7.6%) at admission, and for eight of these patients (3%) other assayed agents were not detected.
When comparing reported drug use on medication charts with detected drug use at admission, a significant difference in the mean number of centrally acting agents was found [0.62 reported (95% CI 0.50-0.75) vs. 1.08 detected (95% CI 0.94-1.22), P < 0.0001 (paired t test)]. The greatest inconsistency between reported and detected drug use was observed for codeine (6.5-fold difference), diazepam (4.8-fold difference) and tramadol (2.1-fold difference) ( Table 3) .
The sex distribution in the hip fracture population was relatively similar to the prescription registry reference population for z-hypnotics/benzodiazepines and codeine/tramadol: 80% vs. 71% females and 75% vs. 65% females, respectively. For antidepressants, the sex distribution was somewhat more divergent: 91% females in the hip fracture population compared to 72% in the reference population. With respect to the age distribution in the two groups, the proportion of the patients aged ≥85 years was 53% in hip fracture patients using z-hypnotics/benzodiazepines compared to 21% in the prescribed reference population. The proportion of patients aged ≥85 years was also higher in the hip fracture patients than the reference population for codeine/tramadol and antidepressants: 40% vs. 18% and 56% vs. 19%, respectively. Statistically significant higher frequencies of centrally acting drugs in plasma of hip fracture patients compared to the reference population were found for nitrazepam OR 2.3, 95% CI 1.3-4.1), mirtazapine (OR 2.3, 95% CI 1.2-4.3) , selective serotonin reuptake inhibitors (SSRIs; OR 1.9, 95% CI 1.3-2.9) and diazepam (OR 1.6, 95% CI 1.1-2.4). No significant differences in frequencies between hip fracture patients and controls were found for z-hypnotics, oxazepam, codeine and tramadol (Table 4) .
The median Na + concentration in patients with antidepressants detected in plasma (n = 41) was almost identical compared to the patients without antidepressants (n = 209): 139 vs. 138 mmol l À1 (Supplementary Figure 1) . The proportion of the patients with Na + concentration below the reference range (137-145 mmol l À1 ) was 17.1% (7/41) in the antidepressant-treated subpopulation compared to 28.2% (59/209) in the remaining patients.
Discussion
In the present study, psychotropic drugs and/or weak opioid analgesics were detected in plasma samples of almost twothirds of older hip fracture patients at hospital admission. Detection frequencies of the benzodiazepines diazepam and nitrazepam, SSRI antidepressants and mirtazapine, were significantly higher than prescription frequencies of the same drugs in an age-, time-and region-matched reference population. Our findings, which were based on objective determination of drug use in hip fracture patients, therefore support what previously has been shown in prescription studies: that treatment with benzodiazepines and antidepressants is associated with increased risk of hip fractures [12, 13] . Prescription studies have also reported an increased risk of hip fractures during use of opioid analgesics, but our study did not find significantly higher frequencies of codeine and tramadol in plasma samples at hospital admission compared to prescription data in the reference population. However, there was a trend towards higher occurrence of tramadol in plasma samples of hip fracture patients compared to its prescription frequency in the reference population (OR 1.5, P = 0.075), while for codeine there was no tendency of increased frequency in hip fracture patients. Although our hip fracture population comprised only 250 patients, this observation might indicate that use of tramadol is more unfavourable than codeine with respect to fall-risk, which is also supported by previous, larger registry-based studies investigating risk of falling/hip fracture in relation to drug prescribing [9, 15] .
Among the included hip fracture patients there was a relatively high discrepancy between reported and detected drugs. The patients generally used more drugs than reported, especially with regards to benzodiazepines, z-hypnotics, codeine and tramadol. Inconsistency between reported drug use and the patients' actual use of drugs has also been shown in other studies of older patients [22] [23] [24] , but not previously in hip fracture patients. The difference between recorded and detected drugs is probably due to the use of on-demand drugs, not included in the medication list. However, information about use of on-demand drugs, which can increase risk of falling, is important to prevent further falls and fractures. Table 3 Consistency between drug use detected by plasma measurements and reported in medical charts in hip fracture patients at hospital admission (n = 250) Psychotropics and weak opioids in plasma samples of hip fracture patients Interestingly, there was also some degree of inconsistency between reported and detected use of antidepressants, since these are agents where stable medication is important to maintain clinical effect and avoid adverse reactions (e.g. withdrawal symptoms/syndrome). For approximately 5% of the included patients, antidepressants were either missing in the charts or recorded when not in use at hospital admission. Although only a minor proportion of the patients were users of antipsychotics, these agents were detected when not reported for half of the users. These examples show that inconsistency between reported and actual use of psychotropics is also an issue for regularly used drugs, and potentially may have serious consequences.
Drug
Use of antidepressants, and particularly SSRIs, have previously been associated with increased risk of hip fractures in studies based on prescription data [7, 12, 25] . However, it is a well-known phenomenon that adherence to treatment with antidepressants is poor, and studies have reported nonadherence as high as 50% among patients treated with antidepressants [19] . This substantial degree of nonadherence implies that studies based on prescription data are subject to considerable uncertainty regarding risk estimates. By being the first study to measure drug intake based on plasma analyses in this patient population, the present investigation objectively shows that use of antidepressants in hip fracture patients is more frequent than prescription frequencies of these drugs in the general elderly population. This is an important finding, since the underlying reason for use of antidepressants increasing risk of hip fracture, is unclear.
The mechanism why use of antidepressants increases the risk of falling and hip fracture among elderly is debated, and a hypothesis from previous studies is that hyponatraemia during treatment with antidepressants, and particularly SSRIs, could induce hypotension and dizziness as an underlying cause of falls [26, 27] . However, in our material, the Na + levels were not lower in the patients with detected antidepressants in plasma compared to the remaining patients. Thus, our observations do not support that hyponatraemia is an important mechanism behind the increased risk of falling and hip fractures among patients using antidepressants. With respect to alcohol, patient history about alcohol consumption is often not reliable. Most previous studies are based on self-reported consumption and not detection in blood, except from a Finnish study where alcohol was detected in blood samples at admission in 19% of men and 16% of women with hip fracture [18] . Serum ethanol was detected at admission in 7.6% in the present study, which is lower than found in the Finnish study [18] . Serum ethanol gives information about alcohol use during the day of fracture, so the information is valuable to consider alcohol-use as a risk factor for the fall. Patients with a daily high intake of alcohol, representing a risk factor also for osteoporosis, will probably also have a positive finding at admission.
The naturalistic nature of the present study implies some methodological weaknesses. One issue is that the time between the last drug intake and blood sampling was unknown, which made it impossible to assess the exposure degree of the measured drugs. Another issue is the unknown and variable time between the falling and hospital admission. Although most blood samples were taken within 24 hours after hip fracture, there was a considerable variability in Table 4 Frequencies of centrally acting drugs detected in plasma samples of hip fracture patients (cases) at admission vs. prescription frequencies of the same drugs in an age-, time-and region-matched population (controls). Odds ratios (OR) estimated by chi-square tests the length of time that passed from the time of hip fracture to the time when the admission samples were taken. In addition, information on the time of fall was lacking for some patients. Consequently, this study might underestimate drug use based on detection in plasma, especially for drugs with a short elimination half-life. Theoretically, administration of on-demand drugs to relieve pain and anxiety between falling and blood sampling at admission might have contributed to an overestimation of drug use, but this is unlikely since, during transport to the hospital, it is standard routine not to give any of the drugs being measured in the study. The case group (hip fracture patients) and control group (reference population) of the study were very imbalanced with respect to size. While only 250 hip fracture patients were included, the reference population comprised around 75 000 patients. Although more well-balanced study groups would have been favourable, a huge control group improves OR estimates. In the reference population, it is also important to be aware that cases of hip fracture were present. It is difficult to estimate the number of hip fracture cases in the reference population, but the annual incidence rate of hip fracture in the South-Eastern Health Region in Norway is reported to be 235 and 572 per 100 000 males and females, respectively [28] . Thus, hip fracture patients represented only a minor proportion of the reference population, and is unlikely to have affected the OR estimates of drug use in cases vs. controls.
In summary, by detection of centrally acting drugs in plasma samples at hospital admission, this study shows that use of antidepressants and benzodiazepines in hip fracture patients is significantly more frequent than respective prescription frequencies among older patients in general. Moreover, psychotropic drugs and weak opioids are often present in plasma of these patients despite no information in the medical record. Comparison of electrolyte levels in users and nonusers of antidepressants does not support that hyponatraemia, which has been associated with use of antidepressants, is of relevance for the increased risk of falling and hip fracture during treatment with these drugs.
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